BridgeBio Pharma stock rating reiterated as Overweight by Wells Fargo

Investing.com - Wells Fargo has reiterated its Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) with a price target of $76.00. The target sits within the broader analyst range of $41-$95, with the consensus maintaining a Strong Buy recommendation.

The research firm maintained its positive outlook on the biopharmaceutical company, which focuses on developing therapies for genetic diseases and cancers with clear genetic drivers.

Wells Fargo analyst Derek Archila affirmed the rating, keeping the same price target that the firm had previously established for BridgeBio shares.

The $76.00 price target suggests significant potential upside for BridgeBio stock from its current trading levels.

BridgeBio’s pipeline includes several clinical-stage drug candidates targeting rare genetic conditions, with the company’s approach centered on addressing diseases at their genetic source. For deeper insights into BridgeBio’s financial health and growth prospects, including exclusive ProTips and comprehensive valuation metrics, visit InvestingPro.

In other recent news, BridgeBio Pharma’s financial outlook has garnered attention from multiple analyst firms. Piper Sandler reaffirmed an Overweight rating on the company, maintaining a price target of $68.00, following discussions with BridgeBio’s management about the launch of their drug, Attruby. The firm noted that the drug’s launch dynamics are strong, with expectations for third-quarter performance to mirror the second quarter. UBS also reiterated a Buy rating and increased its price target from $72.00 to $82.00, identifying BridgeBio as their "top pick" in biotechnology. UBS highlighted the undervalued nature of BridgeBio’s portfolio, emphasizing the Attruby launch and upcoming Phase 3 readouts. Additionally, H.C. Wainwright maintained a Buy rating with a $70.00 price target, focusing on the potential of BridgeBio’s lead candidate, encaleret, for Autosomal Dominant Hypocalcemia Type 1 (ADH1). UBS further described ADH1 as a significant and underappreciated asset within BridgeBio’s portfolio, with Phase 3 data expected this fall. These developments underscore the positive sentiment among analysts regarding BridgeBio’s current and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.